BeiGene
ONC
390.94
-8.76
-2.19%
BeiGene
US · ONC
#538 by market cap
Listed 2016
390.94
-8.76
-2.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Hong Kong Stock Market Movers | BeiGene (06160) Rises Over 3% in Early Trading; Full-Year Revenue Guidance Raised for the Third Time This Year as Innovation Pipeline Approaches Commercialization PhaseZhitong Finance · 2026/11/12
-
Rating change
Major Bank Ratings | UOB Kay Hian: Raises BeiGene’s target price to HKD 300, maintains “Buy” ratingGelonghui Finance · 2026/11/9
-
Rating change
A Quick Look at Today's Ratings for BeiGene(ONC.US), With a Forecast Between $435 to $477Market Newswire · 2026/11/7
-
Company notice
BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDEDSEPTEMBER 30, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATESHKEX · 2026/11/5
-
BeiGene (06160): A total of 15,400 restricted share units in the form of American Depositary Shares were granted under the 2016 Option and Incentive Plan.Zhitong Finance · 2026/11/12
-
Rating change
Research Insights | CSC Financial: Maintains "Buy" rating on BeiGene as innovative pipeline approaches commercialization phaseGelonghui Finance · 2026/11/11
-
Rating change
Morgan Stanley Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $476Market Newswire · 2026/11/13
-
Rating change
BeiGene (06160.HK): Earnings Beat Expectations as High-Speed Growth ContinuesGuojin Securities · 2026/11/5
-
BeiGene (06160) plans to invest USD 19.5 million in Bravera's Series A financing round.Zhitong Finance · 2026/11/16
-
Company notice
BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE MONTHS ENDEDDECEMBER 31, 2025 AND AUDITED RESULTS FOR THE YEARENDED DECEMBER 31, 2025 OFBEONE MEDICINES LTD. AND BUSINESS UPDATESHKEX · 2026/2/26
-
BeiGene Responds to Rumors of County-Level Team Dissolution: Does Not Mean Exit from Broad MarketLatest · 2026/11/20
-
Company notice
BEONE MEDICINES: INSIDE INFORMATION -UNAUDITED RESULTS FOR THE THREE AND NINE MONTHSENDED SEPTEMBER 30, 2025 OFBEONE MEDICINES LTD. AND BUSINESS UPDATESHKEX · 2025/11/6
-
Company notice
BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE AND SIX MONTHSENDED JUNE 30, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATESHKEX · 2026/8/5
-
Company notice
BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE MONTHS ENDEDMARCH 31, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATESHKEX · 2026/5/6
-
Rating change
RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $459Market Newswire · 2026/10/28
-
Rating change
Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $446Market Newswire · 2026/11/6
-
Rating change
Daiwa: Raises BeiGene (06160) target price to HK$286; third-quarter results again beat expectationsZhitong Finance · 2026/11/10
-
Rating change
Major Bank Ratings | Daiwa: BeiGene's Q3 Results Beat Expectations and Full-Year Guidance Raised; Target Price Increased to USD 476Gelonghui Finance · 2026/11/10
-
J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $460Market Newswire · 2026/11/19
-
Rating change
BeiGene (06160.HK): Q3 2026 Results Exceed Expectations; Product Gross Margin Remains HighChun Yee Securities (Hong Kong) · 2026/11/6
-
[Blue Chips] BeiGene (06160.HK) reports a 285% year-on-year increase in net profit to USD 849 million for the first three quarters, raising full-year guidanceAASTOCKS · 2026/11/6
-
Rating change
Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420Market Newswire · 2026/10/9
-
Rating change
BeOne Medicines Ltd (6160) Receives a Buy From UBSTipRanks · 2026/10/21
-
Rating change
RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $459Market Newswire · 2026/10/8
-
Rating change
Truist Financial Maintains BeiGene(ONC.US) With Buy RatingMarket Newswire · 2026/10/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BeiGene discussion 0 comments